Technology area: Biotechnology & Pharmaceuticals
54 pending office actions • 39 clients • 52 examiners • 38 art units • 0 of 54 (0%) have an AI response strategy ready
MORSE, BARNES-BROWN & PENDLETON, P.C. has 55 pending office actions in Biotechnology & Pharmaceuticals and 2368 career applications. Its resolved allowance rate is 81.81%, with an average of 3.65 office actions per allowance.
The profile provides a current docket measure and a substantial career application history. The allowance rate reports resolved outcomes, while the office-action average describes examination activity connected with allowances.
For practitioners, this supports review of biotechnology and pharmaceutical prosecution in terms of active workload, historical results, and examination interaction. The figures are aggregate and therefore do not explain the legal or technical factors affecting particular applications.
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (6%) |
| §103 only | 18 (33%) |
| §102 only | 2 (4%) |
| §112 only | 3 (6%) |
| Double-patenting + other | 6 (11%) |
| Multi-statute (no §101) | 22 (41%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOBLE, MARCIA STEPHENS | 2 | 67.2% | +39.5% |
| PERREIRA, MELISSA JEAN | 2 | 52.1% | +25.7% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| MYERS, CARLA J | 1 | 49.5% | +46.0% |
| YABUT, DIANE D | 1 | 62.6% | +27.4% |
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
| DUBOSE, LAUREN | 1 | 59.1% | +46.2% |
| FIORELLO, BENJAMIN F | 1 | 73.9% | +7.5% |
| MATTSON, SEAN D | 1 | 67.4% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034669 | DUAL TARGETING CHIMERIC ANTIGEN RECEPTORS | HUYNH, PHUONG N | 66d overdue |
| 17182044 | GENE EXPRESSION-BASED BIOMARKER FOR THE DETECTION AND MONITORING OF BRONCHIAL PREMALIGNANT LESIONS | GROSS, CHRISTOPHER M | 53d overdue |
| 18023086 | METHODS OF PREPARING IRON COMPLEXES | SAEED, ALI S | 23d overdue |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | MARTIN, PAUL C | 61d |
| 18701596 | OPTIMIZED BIOSYNTHESIS PATHWAY FOR CANNABINOID BIOSYNTHESIS | LOUNTOS, GEORGE THEMISTOCLIS | 84d |
| 18560883 | ENGINEERED CELLS, ENZYMES, AND METHODS FOR PRODUCING CANNABINOIDS | GORDON, MELENIE LEE | 84d |
| 19407141 | LIGAND-DRUG CONJUGATES | PUTTLITZ, KARL J | — |
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | MYERS, CARLA J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17040967 | METHODS AND ASSAYS FOR MODULATING GENE TRANSCRIPTION BY MODULATING CONDENSATES | PERREIRA, MELISSA JEAN | 16d |
| 19448634 | ARMED CAR-MACROPHAGE COMPOSITIONS AND METHODS OF USE THEREOF | JOHNSON, ALLISON MARIE | — |
| 19407141 | LIGAND-DRUG CONJUGATES | PUTTLITZ, KARL J | — |
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | MYERS, CARLA J | — |
| 19051958 | PERSONALIZED-FIT NASAL DILATOR | YABUT, DIANE D | — |
| 19048696 | PROSTAGLANDIN ANALOGS AND METHODS FOR SUSTAINED GLAUCOMA MANAGEMENT | BAEK, BONG-SOOK | — |
| 18968750 | CONTOUR-FIT NASAL DILATOR | DUBOSE, LAUREN | — |
| 18916572 | REPROGRAMMING OF SOMATIC CELLS | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1632 | 5 |
| 1612 | 3 |
| 1638 | 2 |
| 1682 | 2 |
| 3771 | 2 |
| 1656 | 2 |
| 1654 | 2 |
| 1637 | 2 |
| 1653 | 2 |
| 1623 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19448634 | ARMED CAR-MACROPHAGE COMPOSITIONS AND METHODS OF USE THEREOF | Renabio Therapeutics, Inc. | JOHNSON, ALLISON MARIE | 1638 | §102Other | Non-Final OA | — | Pending | Jan 14, 2026 |
| 19407141 | LIGAND-DRUG CONJUGATES | Tripartite Therapeutics Inc. | PUTTLITZ, KARL J | 1646 | §102§112 | Final Rejection | — | Pending | Dec 03, 2025 |
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | DANA-FARBER CANCER INSTITUTE, INC. | MYERS, CARLA J | 1682 | §101§102§103§112DP | Final Rejection | — | Pending | Nov 21, 2025 |
| 19051958 | PERSONALIZED-FIT NASAL DILATOR | Breathewave Technologies Inc. | YABUT, DIANE D | 3771 | §102§103§112 | Non-Final OA | — | Pending | Feb 12, 2025 |
| 19048696 | PROSTAGLANDIN ANALOGS AND METHODS FOR SUSTAINED GLAUCOMA MANAGEMENT | Peregrine Ophthalmic Pte. Ltd. | BAEK, BONG-SOOK | 1612 | §102§103DP | Non-Final OA | — | Pending | Feb 07, 2025 |
| 18968750 | CONTOUR-FIT NASAL DILATOR | Breathewave Technologies Inc. | DUBOSE, LAUREN | 3771 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 04, 2024 |
| 18861916 | AN APPARATUS PROVIDING COOLING OF SEAWATER SURFACES COMPRISING A BUBBLE CURTAIIN | Oceantherm AS | FIORELLO, BENJAMIN F | 3678 | §102§103§112 | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18916572 | REPROGRAMMING OF SOMATIC CELLS | Whitehead Institute For Biomedical Research | NOBLE, MARCIA STEPHENS | 1632 | §103§112 | Non-Final OA | — | Pending | Oct 15, 2024 |
| 18907240 | METHOD FOR EFFICIENT DRUG ADMINISTRATION ACROSS THE BLOOD-BRAIN BARRIER AND USES THEREOF | Carthera | MATTSON, SEAN D | 3798 | §103 | Final Rejection | — | Pending | Oct 04, 2024 |
| 18885174 | MOBILE INFRARED AND NEGATIVE OXYGEN ION EXPOSURE CHAMBER | Henan Qianpeng Biopharmaceutical Co. Ltd. | MOON, MATTHEW RYAN | 3785 | §103 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18797184 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | LEESER, ERICH A | 1622 | §102DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18832837 | A METHOD OF FORMING A COMPOSITION COMPRISING A PROBIOTIC MICRO-ENCAPSULATED IN A DENATURED PLANT PROTEIN MATRIX | Anabio Technologies Ltd. | WEBB, WALTER E | 1612 | §102§103 | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18773428 | METHODS OF EDITING DNA METHYLATION | Whitehead Institute For Biomedical Research | LEE, JAE W | 1656 | §103§112 | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18734819 | SEAM TAPES AND METHODS OF MAKING THE SAME | Bemis Associates, Inc. | FISCHER, JUSTIN R | 1749 | §103 | Final Rejection | — | Pending | Jun 05, 2024 |
| 18652069 | ADHESIVE PATCH AND METHODS OF MAKING THE SAME | Bemis Associates, Inc. | IMANI, ELIZABETH MARY COLE | 1789 | §103 | Final Rejection | — | Pending | May 01, 2024 |
| 18701596 | OPTIMIZED BIOSYNTHESIS PATHWAY FOR CANNABINOID BIOSYNTHESIS | Cellibre, Inc. | LOUNTOS, GEORGE THEMISTOCLIS | 1652 | §102§103§112 | Non-Final OA | 84d | Pending | Apr 15, 2024 |
| 18635153 | METHODS FOR REPROGRAMMING SOMATIC CELLS | Whitehead Institute For Biomedical Research | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Apr 15, 2024 |
| 18696878 | MIRNA COMBINATION FOR THE PREVENTION AND TREATMENT OF CANCER | Institut National De La Santé Et De La Recherche Medicale | BRETZ, COREY LANE | 1635 | §102§103§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18611871 | METHOD FOR TREATING ZIKA VIRUS INFECTION WITH QUERCETIN-CONTAINING COMPOSITIONS | Quercis Pharma AG | CRAIGO, BAHAR ALAWI | 1699 | §103DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18687807 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | Aimmax Therapeutics, Inc. | BEANE, RANDALL L | §102§103 | Non-Final OA | — | Pending | Feb 28, 2024 | |
| 18587684 | PURIFICATION METHOD OF MYCOBACTERIUM-DERIVED NANOCARRIER PROTEIN | Nankai University | FRONDA, CHRISTIAN L | 1656 | §103§112DP | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18578949 | IMPROVED METHOD FOR PRODUCING A COMPONENT BY MEANS OF ADDITIVE MANUFACTURING | Rwth Aachen | WANG, NICHOLAS A | 1734 | §112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18391648 | METHOD FOR IMPROVING DIABETIC WOUND HEALING USING MIR-200B | Hungkuang University | SAPKOTA, SURAJ | 4100 | §103 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18561857 | PRISTINAMYCIN IA AND FLOPRISTIN COMBINATIONS IN TREATING OR PREVENTING BACTERIAL INFECTIONS | Aimmax Therapeutics, Inc. | BOWLES, DAVID PAUL | 1654 | §103 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18560883 | ENGINEERED CELLS, ENZYMES, AND METHODS FOR PRODUCING CANNABINOIDS | Cellibre, Inc. | GORDON, MELENIE LEE | 1651 | §102§103§112 | Non-Final OA | 84d | Pending | Nov 14, 2023 |
| 18386551 | CHROMOSOME NEIGHBORHOOD STRUCTURES AND METHODS RELATING THERETO | Whitehead Institute For Biomedical Research | GROOMS, TIFFANY NICOLE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18499169 | OPHTHALMIC DRUG DELIVERY CARRIER AND METHOD FOR PREPARING THE SAME | Chang Gung University | LIEB, JEANETTE M | 1654 | §102 | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18495731 | METHODS AND COMPOSITIONS FOR IN VIVO DIRECT GENOME EDITING IN PLANTS | The Regents of the University of California | KUMAR, VINOD | 1663 | §103 | Final Rejection | 96d overdue | Pending | Oct 26, 2023 |
| 18286755 | USE OF ANTIBODY IN ANTI-TUMOR TREATMENT | Ad Pharmaceuticals Co., Ltd. | LI, RUIXIANG | 1674 | §101§103§112Other | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18286405 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | The Children's Hospital of Philadelphia | MARTIN, PAUL C | 1653 | §102§103§112 | Non-Final OA | 61d | Pending | Oct 11, 2023 |
| 18285494 | CHEMICAL REPROGRAMMING OF HUMAN SOMATIC CELLS INTO PLURIPOTENT CELLS | Peking University | MIANO, JOSEPH PAUL | 1631 | §103Other | Final Rejection | — | Pending | Oct 03, 2023 |
| 18374326 | INHIBITORS OF POSITIVE STRAND RNA VIRUSES | National Health Research Institutes | VALLE, ERNESTO | 1623 | §103 | Final Rejection | 34d | Pending | Sep 28, 2023 |
| 18372855 | LIFTING YOKE | Danhydra A/S | VU, STEPHEN A | 3654 | §112 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18231009 | METHOD FOR IMMUNE CELL TRACKING | Megapro Biomedical Co., Ltd. | LEWOCZKO, EVAN MICHAEL | 1612 | §103Other | Final Rejection | 70d | Pending | Aug 07, 2023 |
| 18209360 | POLYPHARMACEUTICAL DRUG COMPOSITIONS AND RELATED METHODS | Aveta Biomics, Inc. | PURDY, KYLE A | 1611 | §103 | Final Rejection | 63d | Pending | Jun 13, 2023 |
| 18038943 | MODULATING TRANSCRIPTIONAL CONDENSATES | Whitehead Institute For Biomedical Research | BUCHANAN, BAILEY CHEYENNE | 1682 | §102§103§112 | Non-Final OA | — | Pending | May 25, 2023 |
| 18034876 | USE OF BRAIN ORGANOIDS AND SINGLE CELL GENOMICS TO UNDERSTAND AND TREAT NEURODEVELOPMENTAL AND NEUROPSYCHIATRIC DISORDERS | Massachusetts Institute Of Technology | KAPUSHOC, STEPHEN THOMAS | 1683 | §103§112 | Non-Final OA | — | Pending | May 01, 2023 |
| 18034669 | DUAL TARGETING CHIMERIC ANTIGEN RECEPTORS | The University of North Carolina at Chapel Hill | HUYNH, PHUONG N | 1641 | §102§103§112 | Final Rejection | 66d overdue | Pending | Apr 28, 2023 |
| 18023086 | METHODS OF PREPARING IRON COMPLEXES | LG Bionano, LLC | SAEED, ALI S | 1616 | §103§112 | Non-Final OA | 23d overdue | Pending | Feb 24, 2023 |
| 18021156 | EX VIVO BRAIN TUMOR MODEL | Massachusetts Institute Of Technology | REGLAS, GILLIAN CHELSEA | 1632 | §102§103§112 | Non-Final OA | — | Pending | Feb 13, 2023 |
| 17945709 | METHOD OF BIOMARKER DETECTION IN COMPANION ANIMALS | Uni Pharma Co., LTD. | HUANG, MICKEY NMN | 1758 | §103 | Final Rejection | 20d | Pending | Sep 15, 2022 |
| 17904035 | Progesterone Combinations | Glia, LLC | HUANG, GIGI GEORGIANA | 1613 | §103DP | Final Rejection | — | Pending | Aug 11, 2022 |
| 17728927 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | The Children's Hospital of Philadelphia | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | — | Pending | Apr 25, 2022 |
| 17770281 | COMPOSITIONS AND METHODS FOR ENHANCING DIFFERENTIATION OF STEM CELL-DERIVED BETA CELLS | President and Fellows of Harvard College | BARRON, SEAN C | 1653 | §103 | Final Rejection | — | Pending | Apr 19, 2022 |
| 17763509 | HYPERBRANCHED CATIONIC POLYMERS USEFUL AS NUCLEIC ACID DELIVERY VECTORS FOR TRANSFECTING CELLS | UNIVERSITY COLLEGE DUBLIN | BAKSHI, PANCHAM | 1623 | §103DP | Non-Final OA | — | Pending | Mar 24, 2022 |
| 17763441 | NANOPARTICLE COMPOSITIONS FOR GENE THERAPY | UNIVERSITY COLLEGE DUBLIN | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Mar 24, 2022 |
| 17588038 | IN VIVO GUIDE RNA LIBRARIES AND METHODS OF MAKING THE SAME | Whitehead Institute For Biomedical Research | DHAR, MATASHA | 1632 | §103 | Non-Final OA | — | Pending | Jan 28, 2022 |
| 17615579 | REPRODUCIBLE BRAIN ORGANOIDS AND METHODS OF MAKING | The Broad Institute, Inc. | BEHARRY, ZANNA MARIA | 1632 | §103§112 | Final Rejection | — | Pending | Nov 30, 2021 |
| 17611560 | METHODS OF CHARACTERIZING AND UTILIZING AGENT-CONDENSATE INTERACTIONS | Whitehead Institute For Biomedical Research | PERREIRA, MELISSA JEAN | 1618 | §103 | Non-Final OA | — | Pending | Nov 15, 2021 |
| 17608463 | PEPTIDE DERIVATIVES AND CONJUGATES THEREOF FOR TREATING CANCER | The University of Sydney | REYNOLDS, FRED H | 1658 | §103 | Non-Final OA | 85d overdue | Pending | Nov 02, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial81.8% of resolved applications prosecuted by Morse, Barnes-Brown & Pendleton, P.C. were allowed, across 2,368 applications in USPTO records.
3.65 office actions per allowed application on average.
54 pending office actions as of October 2026, for 39 clients, before 52 examiners in 38 art units.
